摘要
目的 观察长春瑞滨持续静脉输注加顺铂联合治疗进展期乳腺癌的疗效及毒性。方法 进展期乳腺癌60例，均为浸润性导管癌，初治25例，复治35例；21例应用过含ADM的方案，26例有2个以上部位转移，所有病例接受长春瑞滨10mg静脉注射，随后10mg持续静脉滴注24h，连续5d，共120h，长春瑞滨总剂量60mg，每3周重复。结果 60例共用131周期，完全缓解（CR）3例（5％），部分缓解（PR）22例（37％），缓解率42％（25例），其中中位生存期35周，中位进展时间为19周；剂量限制性毒性为骨髓抑制，白细胞下降率为43％，其中Ⅲ～Ⅳ度为31％（41／131），血小板和血红蛋白亦有不同程度的下降。结论 长春瑞滨持续静脉输注联合顺铂治疗进展期乳腺癌疗效好，毒性较静脉注射低，值得临床推广。
Objective To evaluate the efficacy and toxicity of navebine（NVt3） given by continuous infusion plus cisplatin combination therapy in the treatment of advanced breast cancer. Methods 60 patients with advanced breast cancer were enrolled in this study. The type of his to pathologyis invasive ductal carcinoma. 19 patients had no previous chemotherapy but 21 cases received chemotherapy containing ADM. 26 patients had ≥2 metasta-ticsites. All the patients received vinorelbine according to the following doses chedule： 10rag bolus followed by 10rag by continuous infusion over 24 hours every 5 days every 3 weeks. Results 60 patients were evaluable for response. A total of 131 cycles were administered. The lverall response rate was 41.6 % （3 patients achieved a complete response and 22 patients achieved a partial response）. The median over all survival was 35 weeks and the median duration of response was 19 weeks. The dose limiting toxicity was marrow-suppression. Neutropenia was in 43 % patients （31% was grade Ⅲ and Ⅳ ）. Thrombo-cytopenia and anemia were mild. Conclusion A highe rsponse is obtained in advanced breast cancer treated by continuous intravenous NVB infusion with tolerable toxicity and deserve further revaluation.
出处
《中国基层医药》
CAS
2006年第10期1660-1661,共2页
Chinese Journal of Primary Medicine and Pharmacy
关键词
长春瑞滨
输注
静脉内
乳腺肿瘤
Vinorelbine
Infusions,intravenous
Breast neoplasms
